Literature DB >> 34309877

Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications.

Jianghua Zhou1,2,3, Lan Bai1,3, Xiao-Jing Zhang1,3, Hongliang Li1,3, Jingjing Cai3,4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34309877     DOI： 10.1002/hep.32072

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  11 in total

1.  Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.

Authors:  Thierry Thévenot; Sophie Vendeville; Delphine Weil; Linda Akkouche; Paul Calame; Clémence M Canivet; Claire Vanlemmens; Carine Richou; Jean-Paul Cervoni; Marie-France Seronde; Vincent Di Martino; Jérôme Boursier
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

2.  Evaluated Glomerular Filtration Rate Is Associated With Non-alcoholic Fatty Liver Disease: A 5-Year Longitudinal Cohort Study in Chinese Non-obese People.

Authors:  Ji Cen; Yong Han; Yufei Liu; Haofei Hu
Journal:  Front Nutr       Date:  2022-06-16

3.  Monocyte to High-Density Lipoprotein Cholesterol Ratio at the Nexus of Type 2 Diabetes Mellitus Patients With Metabolic-Associated Fatty Liver Disease.

Authors:  Jue Jia; Ruoshuang Liu; Weiping Wei; Fan Yu; Xiawen Yu; Yirong Shen; Caiqin Chen; Zhensheng Cai; Chenxi Wang; Zhicong Zhao; Dong Wang; Ling Yang; Guoyue Yuan
Journal:  Front Physiol       Date:  2021-12-17       Impact factor: 4.566

4.  Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: a secondary retrospective study.

Authors:  Liling Wu; Man Zhang; Haofei Hu; Qijun Wan
Journal:  Lipids Health Dis       Date:  2021-10-25       Impact factor: 3.876

Review 5.  Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes.

Authors:  Alessandro Mantovani; Andrea Dalbeni; Giorgia Beatrice; Davide Cappelli; Fernando Gomez-Peralta
Journal:  J Clin Med       Date:  2022-02-12       Impact factor: 4.241

6.  Associations Between GGT/HDL and MAFLD: A Cross-Sectional Study.

Authors:  Yuling Xing; Jinhu Chen; Jing Liu; Huijuan Ma
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-09       Impact factor: 3.168

7.  Comparative Efficacy of Chinese Patent Medicines for Clearing Heat and Dampness in the Treatment of NAFLD: A Network Meta-Analysis of Real-World Evidence.

Authors:  Yuan Xu; Yan Wang; Xiao-Jun Gou; Man Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-31       Impact factor: 2.650

8.  High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation.

Authors:  Raphaël Decoin; Laura Butruille; Thomas Defrancq; Jordan Robert; Nicolas Destrait; Augustin Coisne; Samy Aghezzaf; Eloise Woitrain; Zouriatou Gouda; Sofia Schino; Cédric Klein; Patrice Maboudou; François Brigadeau; Didier Klug; Andre Vincentelli; David Dombrowicz; Bart Staels; David Montaigne; Sandro Ninni
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-31       Impact factor: 6.055

9.  Identification of Myocardial Insulin Resistance by Using Liver Tests: A Simple Approach for Clinical Practice.

Authors:  José Raúl Herance; Queralt Martín-Saladich; Mayra Alejandra Velásquez; Cristina Hernandez; Carolina Aparicio; Clara Ramirez-Serra; Roser Ferrer; Marina Giralt-Arnaiz; Miguel Ángel González-Ballester; Juan M Pericàs; Joan Castell-Conesa; Santiago Aguadé-Bruix; Rafael Simó
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

10.  Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort study.

Authors:  Haofei Hu; Changchun Cao; Yong Han; Yongcheng He
Journal:  Front Med (Lausanne)       Date:  2022-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.